Published in Cancer Weekly, June 8th, 1998
RFS 2000 is a second-generation topoisomerase I inhibitor, which causes single-strand breaks in DNA. Median survival to date is 16.2 months among responders, which is the longest survival rate ever reported among pancreatic cancer patients.
Among stable patients, median survival was 9.7 months and among non-responders, 5.9 months. Data shows that among 61 evaluable patients, 33 percent were responders, 30 percent were stable and 37 percent were non-responders following...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.